Status:
UNKNOWN
Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Collaborating Sponsors:
Jiangsu HengRui Medicine Co., Ltd.
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
To investigate the efficacy and safety of carelizumab combined with regorafenib in second-line treatment for patients with primary hepatocellular carcinoma.
Detailed Description
Currently, there is little experience in the application of targeted drugs combined with immunotherapy. Through this study, we hope to explore the optimal population for the use of carelizumab combine...
Eligibility Criteria
Inclusion
- Not convenient to disclose
Exclusion
- Not convenient to disclose
Key Trial Info
Start Date :
May 6 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2022
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT04806243
Start Date
May 6 2021
End Date
January 1 2022
Last Update
June 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NanFang Hospital of Southern Medical University
Guangzhou, Guangdong, China, 510515